Free Trial

hVIVO (HVO) Competitors

hVIVO logo
GBX 19.65 0.00 (0.00%)
(As of 12/20/2024 11:48 AM ET)

HVO vs. SLN, OXB, PRTC, HZD, VRP, ARIX, BVXP, FARN, AVCT, and 4BB

Should you be buying hVIVO stock or one of its competitors? The main competitors of hVIVO include Silence Therapeutics (SLN), Oxford Biomedica (OXB), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Bioventix (BVXP), Faron Pharmaceuticals Oy (FARN), Avacta Group (AVCT), and 4basebio (4BB). These companies are all part of the "biotechnology" industry.

hVIVO vs.

Silence Therapeutics (LON:SLN) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk, community ranking and media sentiment.

In the previous week, Silence Therapeutics and Silence Therapeutics both had 1 articles in the media. Silence Therapeutics' average media sentiment score of 0.00 beat hVIVO's score of -1.11 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Silence Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
hVIVO
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Negative

34.9% of hVIVO shares are owned by institutional investors. 14.0% of hVIVO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

hVIVO has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silence Therapeutics£11.35M0.00N/A-£48.60N/A
hVIVO£67.21M1.99£17.45M£0.03655.00

Silence Therapeutics received 80 more outperform votes than hVIVO when rated by MarketBeat users. However, 69.89% of users gave hVIVO an outperform vote while only 68.81% of users gave Silence Therapeutics an outperform vote.

CompanyUnderperformOutperform
Silence TherapeuticsOutperform Votes
203
68.81%
Underperform Votes
92
31.19%
hVIVOOutperform Votes
123
69.89%
Underperform Votes
53
30.11%

hVIVO has a net margin of 25.96% compared to Silence Therapeutics' net margin of 0.00%. hVIVO's return on equity of 58.04% beat Silence Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Silence TherapeuticsN/A N/A N/A
hVIVO 25.96%58.04%11.97%

Summary

hVIVO beats Silence Therapeutics on 9 of the 11 factors compared between the two stocks.

Get hVIVO News Delivered to You Automatically

Sign up to receive the latest news and ratings for HVO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HVO vs. The Competition

MetrichVIVOBiotechnology IndustryMedical SectorLON Exchange
Market Cap£133.69M£165.68M£5.14B£1.90B
Dividend Yield0.73%3.64%5.09%5.55%
P/E Ratio655.00115.5189.741,818.01
Price / Sales1.9918,531.021,117.09385,452.11
Price / Cash4.9412.8743.1028.51
Price / Book3.288.594.782.78
Net Income£17.45M-£20.67M£120.31M£157.16M
7 Day Performance-9.45%-1.05%-1.92%-2.00%
1 Month Performance-10.68%174.77%13.65%21.18%
1 Year Performance-14.57%134.18%28.34%29.10%

hVIVO Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HVO
hVIVO
N/AGBX 19.65
flat
N/A-12.3%£133.69M£67.21M655.00N/ANews Coverage
Negative News
SLN
Silence Therapeutics
N/AGBX 535
-0.9%
N/AN/A£480.35M£11.35M-11.01100News Coverage
Positive News
High Trading Volume
OXB
Oxford Biomedica
N/AGBX 423.50
flat
GBX 433.33
+2.3%
+116.5%£446.20M£97.28M-295.83891Gap Down
PRTC
PureTech Health
2.2489 of 5 stars
GBX 170
+4.4%
GBX 455
+167.6%
+2.5%£407.01M£3.33M-745.89300News Coverage
High Trading Volume
HZD
Horizon Discovery Group plc (HZD.L)
N/AGBX 184.50
flat
N/AN/A£302.98M£54.63M-33.55416
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/A-1.6822News Coverage
Gap Up
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
BVXP
Bioventix
N/AGBX 3,480.21
+0.7%
N/A-23.7%£181.67M£13.60M2,147.2412
FARN
Faron Pharmaceuticals Oy
N/AGBX 167.70
+1.6%
N/A-45.8%£175.45M£-725,000.00-531.2534
AVCT
Avacta Group
N/AGBX 46.25
+6.5%
N/A-57.2%£165.71M£22.62M-513.33120News Coverage
Negative News
4BB
4basebio
N/AGBX 1,196.50
0.0%
N/A+68.1%£153.27M£311,000.00-1,519.23101Positive News

Related Companies and Tools


This page (LON:HVO) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners